Latest news
FDA Accepts Merck Application to Expand ENFLONSIA Protection Into Second RSV Season - Infection Control TodayInfection Control Today · Mon, 10 Aug 2026 13:03:26 GMTRSV-B Resistance to Nirsevimab Detected in Breakthrough Infections - EMJEMJ · Mon, 10 Aug 2026 09:08:29 GMTFDA Reviews Clesrovimab for Second-Season RSV Prevention in High-Risk Children - Patient Care OnlinePatient Care Online · Sat, 08 Aug 2026 02:54:59 GMTClesrovimab shows comparable safety to palivizumab in high-risk infants across 2 RSV seasons - Contemporary PediatricsContemporary Pediatrics · Fri, 07 Aug 2026 17:56:30 GMTUS FDA accepts supplemental Biologics License Application for Merck’s Enflonsia - PMLiVEPMLiVE · Fri, 07 Aug 2026 10:55:00 GMTSevere Viral Respiratory Illness - Centers for Disease Control and Prevention | CDC (.gov)Centers for Disease Control and Prevention | CDC (.gov) · Fri, 07 Aug 2026 07:00:00 GMTFDA Accepts Merck's Application to Expand Enflonsia into Second RSV Season - BioPharm InternationalBioPharm International · Thu, 06 Aug 2026 16:59:38 GMTFDA accepts application to expand clesrovimab-cfor use to high-risk children in second RSV season - Contemporary PediatricsContemporary Pediatrics · Thu, 06 Aug 2026 14:18:27 GMT